Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
Summary not available.
MAIA Biotechnology (NYSE American: MAIA) has reported promising updates on disease control data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial. The trial is evaluating THIO in sequential combination with cemiplimab for patients with advanced Non-Small Cell Lung Cancer (NSCLC) who have previously failed 2 or more prior lines of treatment.
Key findings include:
- 82% disease control rate: 9 out of 11 patients with post-baseline scans met the primary endpoint of disease control
- Disease control is defined as Complete Response, Partial Response, or Stable Disease per RECIST 1.1
- All patients had previously failed immune checkpoint inhibitor (CPI) and platinum-based chemotherapy treatments
- No new safety analysis was conducted at this time
The company's CEO, Vlad Vitoc, expressed encouragement with these preliminary results, noting that they align with pre-clinical data showing THIO's potential to enhance CPI effectiveness in resistant cases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MAIA Biotechnology, Inc. (NYSE: MAIA) has priced an underwritten public offering of 2,222,200 shares of its common stock at $2.25 per share, aiming to raise approximately $5 million. The offering includes a 45-day option for underwriters to purchase an additional 333,300 shares at the public offering price. The net proceeds will be allocated to fund ongoing clinical trials of THIO, development of second-generation telomere targeting compounds, and general corporate purposes. The offering is expected to close on April 27, 2023. ThinkEquity is serving as the sole book-runner for this offering.
MAIA Biotechnology, Inc. (NYSE American: MAIA) revealed preliminary survival data from the ongoing Phase 2 trial THIO-101, assessing THIO for advanced Non-Small Cell Lung Cancer (NSCLC). The initial two patients remain alive approximately 10 and 9 months post-treatment. Notably, these individuals are Stage IV metastatic cases, previously treated with multiple therapies. The trial has shown that the first six evaluable patients tolerated the THIO high dose without dose-limiting toxicities. Currently, these patients exhibit no disease progression, with reports of 7 and 6 months progression-free survival. These preliminary outcomes suggest potential advancements in treatment options for heavily pretreated lung cancer patients, offering a significant improvement over standard survival rates of 3-4 months.
MAIA Biotechnology has announced the peer-reviewed publication of a study in Molecular Cancer Therapeutics detailing the anticancer effects of THIO in treating Hepatocellular Carcinoma (HCC). The research shows that THIO induces immune responses and can significantly enhance tumor regression, particularly when combined with checkpoint inhibitors.
The results indicate a strong rationale for a clinical trial of THIO in HCC, supported by the US FDA's Orphan Drug Designation. MAIA’s leadership expressed confidence in THIO’s potential as a treatment, emphasizing the findings' relevance to their ongoing clinical development plans.